Myokarditis nach mRNA-Impfung
Tóm tắt
Fallbeschreibung eines 15 Jahre alten Jugendlichen mit Myokarditis 4 Tage nach Erhalt der 2. BNT162b2 mRNA-Impfung (Comirnaty®) ohne erkennbare andere Ursache. Klinisch präsentierte sich der Patient mit thorakalen Schmerzen. Es zeigte sich ein erhöhter Troponin Wert bei erhaltener linksventrikulärer systolischer Funktion. Die kardiale MRT lieferte einen eindeutig pathologischen Befund. Unter symptomatischer Therapie und strenger Bettruhe zeichnete sich ein milder Verlauf mit rasch eintretender Spontanremission ab.
Tài liệu tham khảo
Law Y, Lal A, Chen S, et al. Diagnosis and management of myocarditis in children. Circulation. 2021. https://doi.org/10.1161/CIR.0000000000001001.
Gargano J, Wallace M, Hadler S, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: Update from the advisory committee on immunization practices—United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(27):977–82.
Truong D, Dionne A, Muniz J, et al. Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: Suspected myocarditis after COVID-19 vaccination. Circulation. 2022;145(5):345–56.
Ferreira V, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation. J Am Coll Cardiol. 2018;72(24):3158–76.
Hana D, Patel K, Roman S, et al. Clinical cardiovascular adverse events reported post-COVID-19 vaccination: are they a real risk? Curr Probl Cardiol. 2022;47(3):101077.
Keinath K, Church T, Kurth B, et al. Myocarditis secondary to smallpox vaccination. BMJ Case Rep. 2018; https://doi.org/10.1136/bcr-2017-223523.
Larson K, Ammirati E, Adler E, et al. Myocarditis after BNT162b2 and mRNA-1273 vaccination. Circulation. 2021;144(6):506–8.
Marshall M, Ferguson I, Lewis P, et al. Symptomatic acute myocarditis in 7 adolescents after Pfizer-bioNtech COVID-19 vaccination. Pediatrics. 2021; https://doi.org/10.1542/peds.2021-052478.
Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021;385(23):2132–9.
Husby A, Hansen J, Fosbøl E. SARS-CoV‑2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ. 2021; https://doi.org/10.1136/bmj-2021-068665.
Saeed S, Käsk L, Rajani R, et al. Incidence, clinical presentation and management of myocarditis following mRNA-based Covid-19 vaccines: A brief report. Cardiology. 2022; https://doi.org/10.1159/000522216.
Wallace M, Oliver S. COVID-19 mRNA vaccines in adolescents and young adults: benefit-risk discussion. ACIP meeting. 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/05-COVID-Wallace-508.pdf. Zugegriffen: 10. Apr. 2022.
Public Health England. Information for healthcare professionals on myocarditis and pericarditis following COVID-19 vaccination. Available from Information for healthcare professionals on myocarditis and pericarditis following COVID-19 vaccination—GOV.UK. 2022. www.gov.uk. Zugegriffen: 10. Apr. 2022.
Kerbl R. Myokarditis nach COVID-19-mRNA-Impfung. Monatsschr Kinderheilkd. 2021;169(10):893–4.
Feldstein L, Rose E, Horwitz S, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334–46.
Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA. 2021;325(11):1074.
Dufort E, Koumans E, Chow E, et al. Multisystem inflammatory syndrome in children in New York state. N Engl J Med. 2020;383(4):347–58.
Valverde I, Singh Y, Sanchez-de-Toledo J, et al. Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe. Circulation. 2021;143(1):21–32.